Embecta ($EMBC) 2026 Guidance and Pen Needle Sales Case

Attorneys review the case details to decide whether to proceed with a class action.

D. New Jersey

Court

2:26-cv-07217

Case number

11/25/2025

Class period Start

05/04/2026

Class period End

08/17/2026

Lead Plaintiff motion deadline

$EMBC investors filed a claim against Embecta for overstating the reliability of its 2026 guidance and the strength of its U.S. pen needle business.
After Embecta reported weak second quarter results and cut its 2026 outlook, $EMBC fell 57.8% on May 5, 2026.
$EMBC investors can join this case to be notified about potential recovery.
Case Details:

Between November 25, 2025 and May 4, 2026, Embecta told investors its 2026 financial guidance was aligned with its long-range plan. Executives emphasized stable recurring revenue, a resilient product portfolio, and strength in pen needles, reinforcing the company’s outlook and performance.

However, during this period, investors allege Embecta’s U.S. business was already facing pressure. Embecta allegedly failed to disclose that weakness in the U.S. pen needle market was likely to hurt second-quarter and full-year 2026 results; share loss, softer insulin pen demand, and pricing pressure were weighing on revenue, and the company’s 2026 guidance was unrealistic.

Then, on May 5, 2026, the company revealed second quarter revenue declined 14.4% year over year and lowered its 2026 revenue guidance to $1.015 billion to $1.035 billion. $EMBC fell 57.8%, closing at $3.90. 

Additional analyst reactions followed on May 6, 2026, including reports citing a major miss, U.S. underperformance, pen needle share loss, and a sharp guidance cut. 

By May 5, 2026, shares had dropped to $3.90, representing a total decline of 57.8% over the correction period.

Based on these events, $EMBC investors filed a claim against Embecta, alleging the company:
It overstated the strength of its 2026 outlook.
It failed to warn investors that U.S. pen needle sales were weakening.
It caused investors losses when the company cut guidance and the market reacted.
Investors argue Embecta misled the market about its U.S. pen needle business and 2026 financial outlook, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Attorney Investigation

Alleged Offence

Misleading Statements,

Financial Misrepresentation,

Fraud,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

05/05/2026

Filing date

06/17/2026

Lead Plaintiff Deadline

08/17/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.